Founded in 2020, Inceptor Bio is a biotechnology company developing multiple next-generation cell and gene therapy platforms to deliver cures for underserved and difficult-to-treat cancers. By partnering with universities, medical centers, and industry leaders, Inceptor Bio advances cell and gene therapy programs from discovery-phase technologies into Phase I and II clinical assets. An experienced management team, Scientific Advisory Board, and other Directors and strategic advisors offer industry-leading expertise to partnerships. Inceptor Bio is investing in an Advanced Manufacturing Platform (AMP+) to provide fit-for-purpose, capital-efficient, scalable shared infrastructure to support the advancement of a diversified portfolio of cell therapy platforms across multiple cell types, including CAR-T, CAR-M, and CAR-NK/NKT. Additional information about Inceptor Bio is available at www.inceptor.bio.